Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.

Date Title Source
2022-12-05 4:31:39 am Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting GlobeNewsWire
2022-12-01 4:30:0 am Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA) GlobeNewswire
2022-11-21 1:5:0 pm Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference GlobeNewswire
2022-11-21 4:30:0 am New Survey Reveals the Majority of Myeloma Patients That Undergo Minimal Residual Disease (MRD) Testing Find a Clear Clinical or Emotional Benefit from Results GlobeNewswire
2022-11-03 3:35:10 pm Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Lags Revenue Estimates Zacks
2022-11-03 1:5:0 pm Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results GlobeNewswire
2022-10-11 5:5:0 am Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers GlobeNewswire
2022-10-05 1:5:0 pm Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022 GlobeNewswire
2022-09-15 3:48:47 am Institutional owners may consider drastic measures as Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) recent US$104m drop adds to long-term losses Simply Wall St.